Table 2.

In Vivo Antimalarial Efficacy Using a Single Oral Dose of Trioxane Combined with Mefloquine Hydrochloride or Lumefantrine in P.berghei Infected Mice

trioxane	single oral dose (mg/kg)			survival after infection (days)	avg survival	% parasitemia suppression1
	trioxane	adjuvant	dose
E-26	6	mefloquine	18	16, 35, 37, 60	37.0	>99.9
26	6	mefloquine	18	16, 60, 60, 60	49.0	>99.9
26	6	lumefantrine	18	13, 16, 16, 60	26.3	>99.9
26	150	none	0	7, 7, 9, 10	8.3	98
27	6	mefloquine	18	16, 60, 60, 60	49.0	>99.9
27	6	lumefantrine	18	16, 29, 60, 60	41.3	>99.9
27	150	none	0	7, 60, 60, 60	46.8	>99
28	6	mefloquine	18	15, 29, 60, 60	41	>99.9
30	6	mefloquine	18	18, 20, 20, 37	23.8	>99.9
31	6	mefloquine	18	35, 60, 60, 60	53.8	>99.9
31	150	none	0	7, 60, 60, 60	46.8	>99.9
controls:
vehicle (no drug)	0		0	6, 7, 7, 15	8.8	0
artemether(4b)	6	mefloquine	18	29, 29, 36, 60	38.5	>99.9
artemether(4b)	6	lumefantrine	18	15, 16, 16, 29	19.0	>99.9
mefloquine	0		18	15, 16, 30, 31	23.0	>99.9
lumefantrine	0		18	7, 7, 7, 35	14.0	>99.9

¹ determined on day 3 post infection